Platelet Function Testing and Clinical Outcomes: Connecting the Dots

Affiliations

Editorial

David J Schneider. JACC Basic Transl Sci. 2019.

. 2019 Nov 25;4(7):776-777.

doi: 10.1016/j.jacbts.2019.09.007. eCollection 2019 Nov.

¹ Cardiology Unit, Department of Medicine, Cardiovascular Research Institute, University of Vermont, Burlington, Vermont.

No abstract available

Keywords: diabetes; platelet; thrombin; vorapaxar.

Figures

1. Wisman P.P., Roest M., Asselbergs F.W. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost. 2014;12:736–747. - PubMed
1. Price M.J., Berger P.B., Teirstein P.S., GRAVITAS Investigators Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097–1105. - PubMed
1. Collet J.P., Cuisset T., Rangé G., ARCTIC Investigators Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367:2100–2109. - PubMed
1. Franchi F., Rollini F., Kairouz V. Pharmacodynamic effects of vorapaxar in patients with and without diabetes mellitus: results of the OPTIMUS-5 study. J Am Coll Cardiol Basic Trans Science. 2019;4:763–775. - PMC - PubMed
1. Madsen N.J., Holmes C.E., Serrano F.A., Sobel B.E., Schneider D.J. Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents. Am J Cardiol. 2007;100:722–727. - PubMed